Investor Presentation
74
Investor presentation
First six months of 2022
Protein and peptide expertise combined with oral technology
enables oral amycretin entering phase 1
Amycretin is a GLP-1 and amylin receptor
co-agonist intended for oral delivery
Phase 1 single dose and multiple dose trial for
oral amycretin in obesity initiated in 2022
GLP-1 receptor
Novo NordiskⓇ
People
living with
obesity, and
Multiple ascending dose cohorts
overweight or
otherwise
Single ascending dose cohorts
healthy
Trial objectives
Amylin receptor
•
Assess the safety and tolerability of oral amycretin
Utilising the SNAC technology
PK: Pharmacokinetics; PD: Pharmacodynamics
•
Assess PK profile and explore PD effects
Next steps
•
Phase 1 initiation Q2 2022View entire presentation